Nivolumab (Opdivo®) as monotherapy for unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (2L). HTA ID: 20057
Nivolumab (Opdivo®) as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine and platinum-based combination chemotherapy.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 15/12/2020 |
| Rapid review completed | 13/01/2021 |
| Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that nivolumab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.